Imatinib

Imatinib (Glivec under license, also Imatinib Accord, Imatinib Actavis, Imatinib Medac and Imatinib Teva) is a receptor inhibitor of receptors with tyrosine kinase activity. It is mainly used in the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumour but is also being tested in other indications.